Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,190 across all filing types
Latest filing 2024-02-02 Investor Presentation
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 95% confidence The document is an investor presentation dated February 2, 2024, from Strides Pharma Science Limited. It includes detailed financial data such as revenue, EBITDA, margins, net debt to EBITDA ratios, and growth targets for various fiscal years and periods (FY22, FY23, 9MFY24). It also discusses strategic business segments, market positioning, product pipelines, and growth plans. The document is lengthy (15,000 characters) and contains forward-looking statements, detailed financial metrics, and strategic outlooks typical of investor presentations. There is no indication that this is an official annual report, audit report, earnings release, or regulatory filing. The presence of an investor deck and detailed financial and strategic information aligns with the definition of an Investor Presentation (IP).
2024-02-02 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a short notification letter addressed to stock exchanges regarding the closure of a divestment transaction by the company. It references a previous intimation and confirms the completion of the transaction. The document is brief (1158 characters) and serves as an update on a financing-related event (divestment of a subsidiary). It does not contain financial statements, detailed analysis, or comprehensive report content. Therefore, it is best classified as a Capital/Financing Update (CAP).
2024-02-02 English
Copy of Newspaper Publication
Regulatory Filings
2024-01-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the audio recording of an earnings call for the quarter and nine months ended December 31, 2023. It references the un-audited financial results and provides a link to the recording of the earnings call. The document does not contain the financial results themselves, nor detailed financial data or analysis, but rather is an announcement of the availability of the earnings call recording. According to the classification rules, such a document is best classified as a Call Transcript (CT) type, since it pertains to the earnings call content. However, since this document only provides a link to the audio recording and does not contain the transcript text itself, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is an announcement related to the earnings call but not the transcript itself. The document length is short (1431 characters), and it is an announcement rather than the full transcript or report. Therefore, the best fit is Regulatory Filings (RNS).
2024-01-30 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a submission to stock exchanges (BSE and NSE) regarding a Statement of Deviation/Variation pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It specifically relates to the quarter ended December 31, 2023, and details the utilization of funds raised through a preferential issue of equity warrants. The document is a regulatory compliance disclosure about fund utilization and does not contain financial statements or detailed financial analysis. It is a formal announcement/report required by regulators rather than a full financial report or earnings release. The document length is 4661 characters, which is relatively short and focused on a specific regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-30 English
Allotment of Securities
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement dated January 30, 2024, addressed to stock exchanges regarding the allotment of 14,000 equity shares to employees under a stock option plan. It details the increase in paid-up share capital and confirms that the new shares rank equally with existing shares. There are no financial statements or detailed financial analysis present. The document is an announcement of a capital change (share allotment) rather than a full report or detailed filing. Given the content and length, this fits the category of Share Issue/Capital Change (SHA).
2024-01-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.